Paper Contents
Abstract
ABSTRACTB-Cell Acute Lymphoblastic Leukaemia is generally characterized by presence of Philadelphia chromosome and minor BCR-ABL1 (mBCR-ABL1) fusion gene is a molecular aberration in these patients that influences treatment management and prognosis. Hence, it was aimed to explore clinical relevance of mBCR-ABL1 fusion gene expression in B-ALL patients from western India. Fifty B-ALL patients were enrolled: 14 Pre-treated (PT) patients, 11 treatment non responders (TNR) and 25 treatment responders (TR). Amongst three subgroups of B-ALL patients, mBCR-ABL1 fusion gene copies and %NCN were significantly lower in TR as compared to PT and TNR. Among haematological parameters, PT had significantly higher WBC counts (p<0.001) and lower platelet counts (p<0.001) than TNR and TR groups. Moreover, TR with abnormal WBC counts and platelet counts had lower levels for mBCR-ABL1 fusion copies and %NCN as compared to other groups. Further, Lactate Dehydrogenase activity was found to be significantly higher in PT group in comparison with TR and TNR groups. Moreover, TNR patients having abnormal LDH levels had higher expression of mBCR-ABL1 fusion copies and %NCN as compared to PT and TR subgroups. Therefore, correlation of mBCR-ABL1 fusion gene expression with hematological parameters and LDH activity would be beneficial in treatment monitoring of B-ALL patients.
Copyright
Copyright © 2024 Disha Jethva. This is an open access article distributed under the Creative Commons Attribution License.
